三諾生物(300298.SZ):力爭公司整體銷售收入和經營利潤穩步持續增長
格隆匯7月13日丨三諾生物(300298.SZ)近期在接待機構投資者調研時表示,2023年,公司將在專業化、數智化、全球化三個方面落實關鍵任務,堅持以確保業績健康、持續、穩定增長為核心,圍繞公司發展戰略,努力實現2022年年度報吿中披露的2023年經營目標,即實現營業收入人民幣32億元,力爭公司整體銷售收入和經營利潤穩步持續增長,上述銷售目標不包含心諾健康因納入公司合併報表範圍所增加的營業收入。本經營目標不代表上市公司對2023年度的盈利預測,存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.